WBB Securities rated Sell Seattle Genetics, Inc. (NASDAQ: SGEN) on 08/04/2010, when the stock price was $12.74. Since then, Seattle Genetics, Inc. has gained 223.70% as of 01/14/2016's recent price of $41.24.
If you would have followed this WBB Securities's recommendation on SGEN, you would have lost 69.1% of your investment in 1989 days.

Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.

Marked as spam